Campbell & Co Investment Adviser’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Campbell & Co Investment Adviser’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-9,400	Closed	-$248K	–	957
2021 Q4	$248K	Buy	+9,400	New	+$727K	0.08%	442
2021 Q3	–	Sell	-3,800	Closed	-$538K	–	830
2021 Q2	$538K	Buy	+3,800	New	+$429K	0.22%	132

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Campbell & Co Investment Adviser's RETA Position: Q1 2022 in Review

Campbell & Co Investment Adviser sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2022, closing a stake of 9,400 shares — an estimated $248K sold.

Campbell & Co Investment Adviser first reported a position in RETA in Q2 2021 and held it in 2 quarters. The position peaked at $538K in Q2 2021. 149 funds tracked by Wall St. Rank hold RETA as of Q1 2022.

Campbell & Co Investment Adviser reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2022 after selling out during the quarter.
Campbell & Co Investment Adviser sold 9,400 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2022, an estimated $248K.
Campbell & Co Investment Adviser first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2021 and held it in 2 quarters.
Campbell & Co Investment Adviser's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $538K in Q2 2021.
149 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2022.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2022, filed 9 May 2022.